Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq ® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)

Condition:   Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9 Interventions:   Biological: RotaTeq (V260);   Biological: IPV Sponsor:   Merck Sharp & Dohme Corp. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials